AbbVie Inc. (NYSE:ABBV)‘s stock had its “buy” rating reaffirmed by equities research analysts at Goldman Sachs Group, Inc. (The) in a report released on Friday. They currently have a $100.00 price objective on the stock, up from their prior price objective of $85.00. Goldman Sachs Group, Inc. (The)’s price target would indicate a potential upside of 17.18% from the stock’s current price.

ABBV has been the subject of a number of other reports. Zacks Investment Research downgraded AbbVie from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Vetr raised AbbVie from a “hold” rating to a “buy” rating and set a $76.28 price target for the company in a report on Wednesday, July 26th. Jefferies Group LLC reaffirmed a “buy” rating on shares of AbbVie in a report on Friday, May 26th. Deutsche Bank AG reaffirmed a “hold” rating and set a $66.00 price target (up from $65.00) on shares of AbbVie in a report on Monday, July 17th. Finally, Credit Suisse Group reaffirmed a “hold” rating and set a $65.00 price target on shares of AbbVie in a report on Wednesday, June 7th. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $77.02.

AbbVie (NYSE ABBV) traded up 4.35% during midday trading on Friday, reaching $85.34. The company’s stock had a trading volume of 14,809,087 shares. The firm has a market capitalization of $136.04 billion, a PE ratio of 20.99 and a beta of 1.48. The stock’s 50-day moving average price is $72.74 and its 200 day moving average price is $68.51. AbbVie has a 1-year low of $55.06 and a 1-year high of $86.09.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 28th. The company reported $1.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.02. The company had revenue of $6.94 billion during the quarter, compared to the consensus estimate of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. AbbVie’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.26 EPS. Equities analysts anticipate that AbbVie will post $5.52 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “AbbVie Inc. (ABBV) Earns “Buy” Rating from Goldman Sachs Group, Inc. (The)” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/09/08/abbvie-inc-abbv-earns-buy-rating-from-goldman-sachs-group-inc-the.html.

In related news, Chairman Richard A. Gonzalez sold 193,131 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $71.00, for a total value of $13,712,301.00. Following the transaction, the chairman now owns 469,623 shares in the company, valued at approximately $33,343,233. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Rapp purchased 4,000 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was bought at an average price of $70.45 per share, for a total transaction of $281,800.00. Following the transaction, the director now directly owns 15,498 shares in the company, valued at $1,091,834.10. The disclosure for this purchase can be found here. Insiders sold a total of 490,491 shares of company stock valued at $34,684,639 over the last three months. Company insiders own 0.23% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Beacon Capital Management increased its position in AbbVie by 150.0% in the 4th quarter. Beacon Capital Management now owns 5 shares of the company’s stock valued at $0 after acquiring an additional 3 shares during the period. First Command Financial Services Inc. increased its position in AbbVie by 6.8% in the 1st quarter. First Command Financial Services Inc. now owns 1,565 shares of the company’s stock valued at $102,000 after acquiring an additional 99 shares during the period. CapWealth Advisors LLC increased its position in AbbVie by 55.2% in the 1st quarter. CapWealth Advisors LLC now owns 1,797 shares of the company’s stock valued at $103,000 after acquiring an additional 639 shares during the period. Acropolis Investment Management LLC acquired a new position in AbbVie in the 2nd quarter valued at about $106,000. Finally, Franklin Parlapiano Turner & Welch LLC acquired a new position in AbbVie in the 1st quarter valued at about $108,000. Hedge funds and other institutional investors own 68.29% of the company’s stock.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.